Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma

Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma

Introduction: Naporafenib (LXH254) is an orally bioavailable, type II RAF inhibitor that inhibits both BRAF and CRAF, thereby reducing paradoxical activation and inhibiting the mitogen-activated protein kinase (MAPK) signaling. A phase I and II study showed promising results in the treatment of neur...

Descripció completa

Dades bibliogràfiques
Autors principals: Sabine Hoheisel, Jacopo Roggero, Joanna Mangana, Reinhard Dummer, Lukas Kraehenbuehl, Egle Ramelyte
Format: Article
Idioma:English
Publicat: Elsevier 2025-01-01
Col·lecció:EJC Skin Cancer
Matèries:
Naporafenib
Cutaneous adverse event
Rash
Melanoma
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2772611825000047

Internet

http://www.sciencedirect.com/science/article/pii/S2772611825000047

Ítems similars